Clinical trial
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
NCT00399906 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00399906 |
|---|---|
| Title | A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis |
| Official title | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | BMS-582949, Placebo |
| Enrollment | 99 |
| Start date | Aug 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Nov 15, 2006 |
| Last update posted | Dec 7, 2015 |
| Countries | Australia, Canada, Mexico |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: